352 results on '"Gagliardini, Roberta"'
Search Results
2. Impact of COVID-19 pandemic on retention in care of native and migrant people with HIV in the ICONA cohort
3. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
4. Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications
5. Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study)
6. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort
7. Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network
8. Kinetics of viral DNA in body fluids and antibody response in patients with acute Monkeypox virus infection
9. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)
10. Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study
11. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice
12. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study
13. HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015–21.
14. Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia
15. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital
16. Durability of rilpivirine- versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy
17. Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings
18. Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
19. Pharmacokinetic of Tecovirimat in subjects with Mpox
20. Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study)
21. Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID‐19 booster dose in persons with HIV.
22. Human and Viral microRNA Expression in Acute and Chronic HIV Infections.
23. Risk Awareness as a Key Determinant of Early Vaccine Uptake in the Mpox Vaccination Campaign in an Italian Region: A Cross-Sectional Analysis
24. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV
25. Sexually transmitted infections in people with multidrug-resistant HIV
26. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in PLWH
27. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: data from the ICONA cohort
28. Kinetics of TTV Loads in Peripheral Blood Mononuclear Cells of Early Treated Acute HIV Infections
29. Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications
30. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV
31. Time spent with viral load≤200 copies/mL in a cohort of people with HIV seen for care in Italy during the U=U prevention campaign era
32. Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry
33. SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV
34. HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART
35. Liver fibrosis is associated with cognitive impairment in people living with HIV
36. A Case of Severe Mpox Complicated with Streptococcus pyogenes Sepsis in a Patient with HIV Infection
37. HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network
38. Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox
39. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
40. In cART-Treated HIV-Infected Patients, Immunologic Failure Is Associated With a High Myeloid-Derived Suppressor Cell Frequency.
41. Pharyngo-tonsillar involvement of Mpox in a cohort of men who have sex with men (MSM): A serious risk of missing diagnosis.
42. Pharmacokinetics of tecovirimat in subjects with Mpox
43. Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry
44. The possible effect of sociobehavioral factors and public health actions on the mpox epidemic slowdown
45. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)
46. Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures
47. JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV.
48. Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
49. Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital
50. Immunogenicity and Reactogenicity of Modified Vaccinia Ankara Pre-Exposure Vaccination Against Mpox According to Previous Smallpox Vaccine Exposure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.